MIRA Pharmaceuticals Announces Ketamir-2 Shows Promising Safety Profile in Comparison to Traditional Ketamine In Preclinical Testing

Implications for Patient Care and Market Potential: Economic Impact: With the financial burden of treatment-resistant depression alone accounting for $43.8 billion annually in the U.S., Ketamir-2's development could lead to substantial cost savings in healthcare by providing a more efficient and safer treatment alternative. MIRA is on track to submit an IND application for Ketamir-2 to the FDA by the end of this year. This submission will mark a significant milestone in advancing Ketamir-2 toward clinical t ...